(Morning stocks to watch updated to reflect share price changes and additional stock mentions)
NEW YORK (TheStreet) -- Boston Scientific (BSX) - Get Report was advancing by 3.4% to $6.74 in premarket trading ahead of its investor meeting on Friday before the market open. On Wednesday, the company said that a subsidiary it recently bought, Asthmatx, which focuses on asthma treatments, was awarded the 2010 Popular Science"Best of What's New" Award in the health category for its Alair Bronchial Thermoplasty System.
Shares of Boston Scientific were swinging wildly in per-market trading, and were up by 1.1% at $6.59 just prior to the market open.
was rising by 2.4% to $37.61 after the regional bank said it was raising its quarterly dividend to 10 cents a common share from the previous dividend of 5 cents a share and was buying back 7% percent of its outstanding common stock.
Fifth Third Bancorp
was gaining 1.7% to $12.89 in premarket trading. On Tuesday, a
report said the regional bank was among the most improved in credit quality among its peer group over recent quarters.
were slightly higher at $55, up 2.3%, after the discount retailer reported better-than-expected third-quarter earnings. Net income rose by about 23% to $535 million, or 74 cents a share, from $436 million, or 58 cents a share, the same period last year. Sales rose by about 3% to $15.2 billion from $14.8 billion a year ago.
Analysts, on average, expected earnings of 68 cents a share on sales of $15.61 billion.
shares were advancing prior to the market open, up **1.3% to $39.03,** after its partner on drugs,
Human Genome Sciences
( HGSI), received votes in favor of its proposed lupus treatment Benlysta from the Food and Drug Administration.
However, Human Genome shares were falling 7.3% to $23.98 in premarket trading Wednesday
The stock received two downgrades before the market open, one by
and the other by
Bank of America Merrill Lynch
was slumping by 3.7% to $4.62 in premarket trading after the company said it plans to sell additional common stock. The Aliso Viejo, Calif.-based drug developer didn't provide any further details about the plan except to say that Jefferies would be the sole book-runner on the deal with four other firms, including Canaccord Genuity and Merriman Capital as co-managers.
was falling by 2.2% to $55.75 after the Chinese online media company topped Wall Street's third-quarter earnings expectations but provided less-than-expected revenue projections for the December period.
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.